Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office (EPO) has issued a new patent to Kinaxo Biotechnologies, covering technologies which are exclusively marketed by the company under the trademarks Cellular Target Profiling, KinAffinity and Epigenetics Target Profiling.
Subscribe to our email newsletter
The new patent, entitled ‘Proteome-wide quantification of small molecule binding to cellular target proteins,’ (EP2045332B1) supports company’s chemical proteomics solutions for research and development.
Cellular Target Profiling enables selectivity analysis and prediction of off-target liabilities for compounds with an unclear target spectrum.
Kinaxo CTO Henrik Daub said the company’s experience and expertise deliver powerful insights into cellular small molecule target interactions and such knowledge supports decision-making at various stages of the drug development process.